The advent of biologic drugs has revolutionized the treatment of Inflammatory Bowel Disease, increasing rates of response and mucosal healing in comparison to conventional therapies by allowing the treatment of corticosteroid-refractory cases and reducing corticosteroid-related side effects. However, biologic therapies (anti-TNF alpha inhibitors, anti-alpha 4 beta 7 integrin and anti-IL12/23) are still burdened by rates of response that hover around 40% (in biologic-naive patients) or lower (for biologic-experienced patients). Moreover, knowledge of the mechanisms underlying drug resistance or loss of response is still scarce. Several cellular and molecular determinants are implied in therapeutic failure; genetic predispositions, in the form of single nucleotide polymorphisms in the sequence of cytokines or Human Leukocyte Antigen, or an altered expression of cytokines and other molecules involved in the inflammation cascade, play the most important role. Accessory mechanisms include gut microbiota dysregulation. In this narrative review of the current and most recent literature, we shed light on the mentioned determinants of therapeutic failure in order to pave the way for a more personalized approach that could help avoid unnecessary treatments and toxicities.
Puca, P., Capobianco, I., Coppola, G., Di Vincenzo, F., Trapani, V., Petito, V., Laterza, L., Pugliese, D., Lopetuso, L. R., Scaldaferri, F., Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease, <<INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES>>, 2024; 25 (5): N/A-N/A. [doi:10.3390/ijms25052789] [https://hdl.handle.net/10807/268474]
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease
Puca, Pierluigi;Capobianco, Ivan;Coppola, Gaetano;Di Vincenzo, Federica;Trapani, Valentina;Petito, Valentina;Laterza, Lucrezia;Pugliese, Daniela;Lopetuso, Loris Riccardo;Scaldaferri, Franco
2024
Abstract
The advent of biologic drugs has revolutionized the treatment of Inflammatory Bowel Disease, increasing rates of response and mucosal healing in comparison to conventional therapies by allowing the treatment of corticosteroid-refractory cases and reducing corticosteroid-related side effects. However, biologic therapies (anti-TNF alpha inhibitors, anti-alpha 4 beta 7 integrin and anti-IL12/23) are still burdened by rates of response that hover around 40% (in biologic-naive patients) or lower (for biologic-experienced patients). Moreover, knowledge of the mechanisms underlying drug resistance or loss of response is still scarce. Several cellular and molecular determinants are implied in therapeutic failure; genetic predispositions, in the form of single nucleotide polymorphisms in the sequence of cytokines or Human Leukocyte Antigen, or an altered expression of cytokines and other molecules involved in the inflammation cascade, play the most important role. Accessory mechanisms include gut microbiota dysregulation. In this narrative review of the current and most recent literature, we shed light on the mentioned determinants of therapeutic failure in order to pave the way for a more personalized approach that could help avoid unnecessary treatments and toxicities.File | Dimensione | Formato | |
---|---|---|---|
ijms-25-02789.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
1.93 MB
Formato
Adobe PDF
|
1.93 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.